You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,486,475


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,486,475
Title:PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
Abstract: The present invention relates to a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof for use in the amelioration, treatment, or prevention of adverse neurological events caused by administering an antibody or fragment thereof comprising a CD3 binding domain, including a CD19 x CD3 bispecific single chain antibody, such as blinatumomab. PPS is a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans. Kits comprising a PPS, an antibody or fragment thereof comprising a CD3 binding domain, and instructions for administration, which indicate that the PPS is to be employed for the amelioration, treatment or prevention of adverse neurological events caused by administering the antibody or fragment thereof comprising said CD3 binding domain, are also disclosed.
Inventor(s): Kufer; Peter (Munich, DE), Nagorsen; Dirk (Munich, DE), Scheele; Juergen (Munich, DE), Zugmaier; Gerhard (Munich, DE), Klinger; Matthias (Gilching, DE), Hoffmann; Patrick (Bad Heilbrunn, DE), Naegele; Virginie (Munich, DE), Dopfer; Elaine-Pashupati (Munich, DE)
Assignee: AMGEN RESEARCH (MUNICH) GMBH (Munich, DE)
Application Number:14/176,089
Patent Claims:1. A method for ameliorating, treating, or preventing adverse neurological events in a patient caused by administering blinatumomab to the patient, the method comprising administering an effective amount of pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein said PPS is pentosanpolysulfate sodium.

3. The method of claim 2, wherein said patient is a human.

4. The method of claim 2, wherein said patient has a B/T-cell ratio of less than 1:5.

5. The method of claim 1, wherein said adverse neurological events is one or more of tremor, apraxia, ataxia, aphasia, hallucination and seizure.

6. The method of claim 5, wherein said patient is a human.

7. The method of claim 5, wherein said patient has a B/T-cell ratio of less than 1:5.

8. The method of claim 1, wherein said patient is a human.

9. The method of claim 1, wherein said patient has a B/T-cell ratio of less than 1:5.

10. The method of claim 1, wherein the PPS is selected from the group consisting of: (a) a PPS of formula (1) ##STR00004## wherein R represents --SO.sub.3Y and Y is H or a pharmaceutically acceptable cation; (b) a PPS of formula (2) ##STR00005## and (c) a PPS of formula (3) ##STR00006## wherein n as shown in formula (1) and (2) is a number that results in a PPS with a molecular weight of 4000 to 6000 Dalton.

11. The method of claim 10, wherein the pharmaceutically acceptable cation is sodium, potassium, or magnesium.

12. A kit comprising a pentosanpolysulfate (PPS) or a pharmaceutically acceptable salt thereof and blinatumomab and either instructions for administration or an imprint indicating that the PPS or the pharmaceutically acceptable salt thereof is to be employed for ameliorating, treating, or preventing-adverse neurological events caused by blinatumomab.

13. The kit of claim 12, wherein the PPS is selected from the group consisting of: (a) a PPS of formula (1) ##STR00007## wherein R represents --SO.sub.3Y and Y is H or a pharmaceutically acceptable cation; (b) a PPS of formula (2) ##STR00008## and (c) a PPS of formula (3) ##STR00009## wherein n as shown in formula (1) and (2) is a number that results in a PPS with a molecular weight of 4000 to 6000 Dalton.

14. The kit of claim 13, wherein the pharmaceutically acceptable cation is sodium, potassium, or magnesium.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.